MVCD4
MCID: MCR133
MIFTS: 41

Microvascular Complications of Diabetes 4 (MVCD4)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 4

MalaCards integrated aliases for Microvascular Complications of Diabetes 4:

Name: Microvascular Complications of Diabetes 4 56 73 29 13 6 39
Diabetic Nephropathy 73 71
Mvcd4 56 73
Microvascular Complications of Diabetes, Susceptibility to, 4 56
Nephropathy, Diabetic, Susceptibility to 56
Nephropathy, Diabetic 56

Classifications:



External Ids:

OMIM 56 612628
OMIM Phenotypic Series 56 PS603933
MeSH 43 D048909
UMLS 71 C0011881

Summaries for Microvascular Complications of Diabetes 4

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 4: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 4, also known as diabetic nephropathy, is related to atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 4 is IL1RN (Interleukin 1 Receptor Antagonist). The drugs Pioglitazone and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612628 PS603933

Related Diseases for Microvascular Complications of Diabetes 4

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 4 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease 12.3
2 microvascular complications of diabetes 3 12.1
3 microvascular complications of diabetes 7 12.0
4 microvascular complications of diabetes 6 11.9
5 microvascular complications of diabetes 5 11.6
6 diabetic angiopathy 11.6
7 microvascular complications of diabetes 1 11.4
8 microvascular complications of diabetes 2 11.4
9 end stage renal disease 10.6
10 hypertension, essential 10.5
11 iga glomerulonephritis 10.5
12 kidney hypertrophy 10.4
13 autonomic neuropathy 10.4
14 pre-eclampsia 10.4
15 nephrosclerosis 10.4
16 diabetic neuropathy 10.4
17 hyperuricemia 10.3
18 atherosclerosis susceptibility 10.3
19 cytokine deficiency 10.3
20 hypoglycemia 10.3
21 proteasome-associated autoinflammatory syndrome 1 10.3
22 rickets 10.3
23 hyperglycemia 10.3
24 diabetes mellitus 10.3
25 hypertriglyceridemia, familial 10.3
26 yemenite deaf-blind hypopigmentation syndrome 10.3
27 muscle hypertrophy 10.3
28 glucose intolerance 10.3
29 congestive heart failure 10.3
30 arteries, anomalies of 10.3
31 cerebrovascular disease 10.3
32 wilms tumor 5 10.3
33 hyperlipoproteinemia, type iii 10.3
34 lipoprotein quantitative trait locus 10.3
35 focal segmental glomerulosclerosis 10.3
36 rapidly involuting congenital hemangioma 10.3
37 systemic lupus erythematosus 10.2
38 homocysteinemia 10.2
39 kidney disease 10.2
40 b-cell lymphoma 10.2
41 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
42 creatinine clearance quantitative trait locus 10.2
43 cardiovascular system disease 10.2
44 deficiency anemia 10.2
45 eclampsia 10.2
46 fatty liver disease 10.2
47 autoimmune disease 10.2
48 wilms tumor 1 10.2
49 body mass index quantitative trait locus 1 10.2
50 coronary heart disease 1 10.2

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 4:



Diseases related to Microvascular Complications of Diabetes 4

Symptoms & Phenotypes for Microvascular Complications of Diabetes 4

Clinical features from OMIM:

612628

Drugs & Therapeutics for Microvascular Complications of Diabetes 4

Drugs for Microvascular Complications of Diabetes 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
6
Methyldopa Approved Phase 4 555-30-6 38853
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Capsaicin Approved Phase 4 404-86-4 1548943
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
11
Probucol Approved, Investigational Phase 4 23288-49-5 4912
12
Ramipril Approved Phase 4 87333-19-5 5362129
13
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
14
Doxazosin Approved Phase 4 74191-85-8 3157
15
Atorvastatin Approved Phase 4 134523-00-5 60823
16
Indapamide Approved Phase 4 26807-65-8 3702
17
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
18
Nisoldipine Approved Phase 4 63675-72-9 4499
19
Trandolapril Approved Phase 4 87679-37-6 5484727
20
Amlodipine Approved Phase 4 88150-42-9 2162
21
Verapamil Approved Phase 4 52-53-9 2520
22
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
23
Insulin glulisine Approved Phase 4 207748-29-6
24
Insulin glargine Approved Phase 4 160337-95-1
25
Liraglutide Approved Phase 4 204656-20-2 44147092
26
Nitric Oxide Approved Phase 4 10102-43-9 145068
27
Allopurinol Approved Phase 4 315-30-0 2094
28
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
29
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
30
Insulin lispro Approved Phase 4 133107-64-9
31
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
32
Clonidine Approved Phase 4 4205-90-7 2803
33
Atenolol Approved Phase 4 29122-68-7 2249
34
Glimepiride Approved Phase 4 93479-97-1 3476
35
Hydralazine Approved Phase 4 86-54-4 3637
36
Terazosin Approved Phase 4 63590-64-7 5401
37
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
39
Febuxostat Approved Phase 4 144060-53-7 134018
40
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
41
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
42
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
43
Canagliflozin Approved Phase 4 842133-18-0
44
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
45
Gliclazide Approved Phase 4 21187-98-4 3475
46
Adenosine Approved, Investigational Phase 4 58-61-7 60961
47
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
48
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
49
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
50
Valsartan Approved, Investigational Phase 4 137862-53-4 60846

Interventional clinical trials:

(show top 50) (show all 396)
# Name Status NCT ID Phase Drugs
1 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
2 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
5 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
6 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
7 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
8 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
9 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
10 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
11 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
12 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
13 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
14 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
15 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
16 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
17 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
18 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
19 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
20 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
21 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
22 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
23 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
24 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
25 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
26 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
27 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
28 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
29 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
30 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
31 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
32 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
33 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
34 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
35 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
36 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
37 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
38 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
39 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
40 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
41 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
42 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
43 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
44 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
45 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
46 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4 Amlodipine;Valsartan
47 Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose Completed NCT01738945 Phase 4 Amlodipine
48 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
49 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
50 Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes Completed NCT02796170 Phase 4 Dapagliflozin;Sulfonylurea;Placebo

Search NIH Clinical Center for Microvascular Complications of Diabetes 4

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 4

Genetic tests related to Microvascular Complications of Diabetes 4:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 4 29 IL1RN

Anatomical Context for Microvascular Complications of Diabetes 4

MalaCards organs/tissues related to Microvascular Complications of Diabetes 4:

40
Kidney, Endothelial, Pancreas, Bone, Heart, Liver, Monocytes

Publications for Microvascular Complications of Diabetes 4

Articles related to Microvascular Complications of Diabetes 4:

(show top 50) (show all 18120)
# Title Authors PMID Year
1
Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. 56 6 61
15286433 2004
2
Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. 61 6 56
8786086 1996
3
Interleukin-1 system gene polymorphisms are associated with fat mass in young men. 6
16636119 2006
4
Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. 6
10750554 2000
5
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 6
10746728 2000
6
Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. 6
10025794 1999
7
Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. 6
8500797 1993
8
miR-136 improves renal fibrosis in diabetic rats by targeting down-regulation of tyrosine kinase SYK and inhibition of TGF-β1/Smad3 signaling pathway. 61
32441195 2020
9
Sleeve Gastrectomy Attenuates Diabetic Nephropathy by Upregulating Nephrin Expressions in Diabetic Obese Rats. 61
32399849 2020
10
Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy. 61
32446112 2020
11
Baicalin attenuates fibrogenic process in human renal proximal tubular cells (HK-2) exposed to diabetic milieu. 61
32360619 2020
12
Esculin reduces P2X7 and reverses mitochondrial dysfunction in the renal cortex of diabetic rats. 61
32417372 2020
13
Cathepsin C is a novel mediator of podocyte and renal injury induced by hyperglycemia. 61
32302668 2020
14
Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. 61
31939197 2020
15
Baicalin serves a protective role in diabetic nephropathy through preventing high glucose-induced podocyte apoptosis. 61
32550886 2020
16
Implications of immunoglobulin G deposit in glomeruli in Chinese patients with diabetic nephropathy. 61
32031751 2020
17
Circ_0000285 promotes podocyte injury through sponging miR-654-3p and activating MAPK6 in diabetic nephropathy. 61
32275999 2020
18
12-Lipoxygenase as a key pharmacological target in the pathogenesis of diabetic nephropathy. 61
32333927 2020
19
Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. 61
32339782 2020
20
Akebia Saponin D ameliorated kidney injury and exerted anti-inflammatory and anti-apoptotic effects in diabetic nephropathy by activation of NRF2/HO-1 and inhibition of NF-KB pathway. 61
32344355 2020
21
Decreased plasma kallikrein activity is associated with reduced kidney function in individuals with type 1 diabetes. 61
32270254 2020
22
Knockdown of CTRP6 inhibits high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation in mesangial cells through regulating the Akt/NF-κB pathway. 61
32077518 2020
23
PKM2 Activator TEPP-46 Attenuates Thoracic Aortic Aneurysm and Dissection by Inhibiting NLRP3 Inflammasome-Mediated IL-1β Secretion. 61
32323562 2020
24
AMPK in microvascular complications of diabetes and the beneficial effects of AMPK activators from plants. 61
30935723 2020
25
Exosomes from high glucose-treated macrophages activate macrophages andinduce inflammatory responses via NF-κB signaling pathway in vitro and in vivo. 61
32388490 2020
26
Efficacy and safety of a mother-child technique for recanalization of chronic central venous occlusive disease in hemodialysis patients. 61
31848120 2020
27
Modulation of proteomic and inflammatory signals by Bradykinin in podocytes. 61
32518694 2020
28
Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets. 61
32418621 2020
29
β-Caryophyllene inhibits high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation in mesangial cells. 61
32416450 2020
30
The TGF-β profibrotic cascade targets ecto-5'-nucleotidase gene in proximal tubule epithelial cells and is a traceable marker of progressive diabetic kidney disease. 61
32289379 2020
31
Loganin and catalpol exert cooperative ameliorating effects on podocyte apoptosis upon diabetic nephropathy by targeting AGEs-RAGE signaling. 61
32277978 2020
32
Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy. 61
32545818 2020
33
Nomogram for the prediction of diabetic nephropathy risk among patients with type 2 diabetes mellitus based on a questionnaire and biochemical indicators: a retrospective study. 61
32484786 2020
34
Association of serum sestrin 2 and betatrophin with serum neutrophil gelatinase associated lipocalin levels in type 2 diabetic patients with diabetic nephropathy. 61
32548072 2020
35
Assessment and comparison of the antioxidant defense system in patients with type 2 diabetes, diabetic nephropathy and healthy people: A case-control study. 61
32359740 2020
36
Baicalin suppresses renal fibrosis through microRNA-124/TLR4/NF-κB axis in streptozotocin-induced diabetic nephropathy mice and high glucose-treated human proximal tubule epithelial cells. 61
32500512 2020
37
Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A. 61
32358041 2020
38
Erratum: Yoon, J.J., et al. Dianthus superbus Improves Glomerular Fibrosis and Renal Dysfunction in Diabetic Nephropathy Model. Nutrients 2019, 11, 553. 61
32503102 2020
39
TNF-α pathway and T-cell immunity are activated early during the development of diabetic nephropathy in Type II Diabetes Mellitus. 61
32304735 2020
40
Nepeta angustifolia C. Y. Wu improves renal injury in HFD/STZ-induced diabetic nephropathy and inhibits oxidative stress-induced apoptosis of mesangial cells. 61
32201300 2020
41
Erratum. Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic MicroRNAs Among Extracellular Vesicles, HDL, and Ago-2. Diabetes 2019;68:2287-2300. 61
32522718 2020
42
LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy. 61
32504027 2020
43
Increased urinary miR-196a level predicts the progression of renal injury in patients with diabetic nephropathy. 61
30521014 2020
44
Sodium-glucose co-transporters and diabetic nephropathy: Is there a link with toll-like receptors? 61
31968131 2020
45
The role of activation of KАTP channels on hydrogen sulfide induced renoprotective effect on diabetic nephropathy. 61
31774182 2020
46
[Medication adherence and physician-pharmacist collaboration. Focus on the patient with diabetic nephropathy]. 61
32520461 2020
47
Gongronema latifolium leaf extract modulates hyperglycaemia, inhibits redox imbalance and inflammation in alloxan-induced diabetic nephropathy. 61
32550199 2020
48
Diabetes-induced upregulation of kallistatin levels exacerbates diabetic nephropathy via RAS activation. 61
32352602 2020
49
Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy. 61
32555442 2020
50
Calcitriol attenuates renal tubular epithelial cells apoptosis via inhibiting p38MAPK signaling in diabetic nephropathy. 61
32556611 2020

Variations for Microvascular Complications of Diabetes 4

ClinVar genetic disease variations for Microvascular Complications of Diabetes 4:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL1RN IL1RN, IVS2, 86-BP DUPduplication Pathogenic,risk factor 14674

Expression for Microvascular Complications of Diabetes 4

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 4.

Pathways for Microvascular Complications of Diabetes 4

GO Terms for Microvascular Complications of Diabetes 4

Sources for Microvascular Complications of Diabetes 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....